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Abstract
 
We previously reported that interleukin (IL)-4 upregulates the expression of leukotriene C
 
4
 
synthase (LTC
 
4
 
S) by human cord blood–derived mast cells (hMCs), augments their high-affin-
 
ity Fc receptor for IgE (Fc
 
 
 
RI)-dependent generation of eicosanoids and cytokines, and induces
a calcium flux in response to cysteinyl leukotrienes (cys-LTs) and uridine diphosphate (UDP)
that is blocked by cys-LT receptor antagonists. We speculated that this IL-4–dependent, recep-
tor-mediated response to the cys-LTs and UDP might induce cytokine generation by hMCs
without concomitant exocytosis. Unlike hMCs maintained in cytoprotective stem cell factor
(SCF) alone, hMCs primed for 5 d with IL-4 responded to UDP (1 
 
 
 
M), LTC
 
4
 
 (100 nM), and
LTD
 
4
 
 (100 nM) by producing IL-5, tumor necrosis factor (TNF)-
 
 
 
, and especially large quan-
tities of macrophage inflammatory protein (MIP)-1
 
 
 
 de novo at 6 h, preceded by the induced
expression of the corresponding mRNAs. Cys-LT– and UDP-mediated cytokine production
by the primed hMCs occurred without histamine release or PGD
 
2
 
 generation and was inhibited
by the CysLT1 receptor antagonist MK571. Additionally, pretreatment of hMCs with MK571
or with the cys-LT biosynthetic inhibitor MK886 decreased IL-5 and TNF-
 
 
 
 production in re-
sponse to IgE receptor cross-linkage, implying a positive feedback by endogenously produced
cys-LTs. Cys-LTs and UDP thus orchestrate a novel, IL-4–regulated, non-IgE–dependent
hMC activation for cytokine gene induction that could be initiated by microbes, cellular injury,
or neurogenic or inflammatory signals; and this pathobiologic event would not be recognized
in tissue studies where hMC activation is classically defined by exocytosis.
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Introduction
 
Mast cells (MCs)
 
*
 
 are bone marrow–derived immune effec-
tor cells that are prominent at the interfaces between the
immune system and the external environment, such as the
skin and the gastrointestinal and respiratory tracts. Rodent
and human MCs activated in vitro by cross-linkage of their
high-affinity Fc receptor for immunoglobulin E (Fc
 
 
 
RI)
release preformed histamine and proteases from secretory
granules; generate the arachidonic acid–derived eicosanoid
mediators PGD
 
2
 
 and cysteinyl leukotrienes (cys-LTs; for a
review, see reference 1); and subsequently transcribe, trans-
late, and secrete several proinflammatory cytokines and
chemokines (2, 3). Eicosanoid generation is initiated by a
calcium-dependent cytosolic phospholipase A
 
2
 
 (cPLA
 
2
 
)
that liberates arachidonic acid from membrane phospholip-
ids (4). For cys-LT generation, 5-lipoxygenase (5-LO) acts
in concert with the 5-LO–activating protein (FLAP) (5) to
convert arachidonic acid sequentially to the unstable inter-
mediates 5-hydroperoxyeicosatetraenoic acid (5-HPETE)
and then leukotriene (LT)A
 
4
 
 (6). In MCs, eosinophils, and
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Abbreviations used in this paper:
 
 Cys-LT, cysteinyl leukotriene; CysLTR
 
IL-4
 
,
IL-4–regulated receptor-mediated response to Cys-LTS and UDP; ERK,
extracellular regulated kinase; Fc
 
 
 
RI, high affinity Fc receptors for IgE;
FLAP, 5-lipoxygenase activating protein; hMCs, human mast cells; LT,
leukotriene; LTC
 
4
 
S, LTC
 
4
 
 synthase; MC, mast cell; MIP, macrophage
inflammatory protein; NF-AT, nuclear factor of activated T cells; SCF,
stem cell factor; UDP, uridine diphosphate. 
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basophils, LTA
 
4
 
 is conjugated to reduced glutathione to
form LTC
 
4
 
 by LTC
 
4
 
 synthase (LTC
 
4
 
S) (7–9), an integral
nuclear membrane protein with homology to FLAP. LTC
 
4
 
is released by a distinct cellular export mechanism (10) and
metabolized sequentially to LTD
 
4
 
 by either extracellular
 
 
 
-glutamyl transferase or 
 
 
 
-glutamyl leukotrienase (11, 12),
and then by a dipeptidase to LTE
 
4
 
 (13). LTC
 
4
 
, LTD
 
4
 
, and
LTE
 
4
 
 then act through at least two 7 transmembrane-span-
ning G protein–coupled receptors, termed the CysLT1 and
CysLT2 receptors (14, 15). The bronchoconstriction (16)
and alterations in venular permeability (17) mediated by
the cys-LTs reflect their effects at smooth muscle– and mi-
crovasculature-associated receptors. Cys-LT receptors are
also expressed by hematopoietic cells, such as eosinophils,
basophils, monocytes, and CD34-bearing progenitor cells
(14, 15, 18, 19). They have been implicated in leukocyte
recruitment on the basis of responses to cys-LTs in vitro
(19) and in vivo (20). However, whether cys-LT receptors
on hematopoietic immune effector cells might serve addi-
tional proinflammatory functions is not known.
The culture of cord blood mononuclear cells for 6–9 wk
with recombinant stem cell factor (SCF), IL-6, and IL-10
results in the development of pure, mature human MCs
(hMCs) (21). When these cells were primed for 5 d with
recombinant IL-4 (10 ng/ml) in the continued presence of
SCF, their IgE-dependent exocytosis and PGD
 
2
 
 generation
increased by four- and twofold, respectively, compared
with replicates maintained in SCF alone (22). However,
IL-4 augmented the cys-LT–generating capability of hMCs
by more than 25-fold, due to a profound induction
of LTC
 
4
 
S transcript, protein, and function (22). The
unprimed hMCs expressed both CysLT1 receptor mRNA
and protein and responded to either LTC
 
4
 
 or LTD
 
4
 
 with a
sustained calcium flux that was completely blocked by the
selective CysLT1 receptor antagonist MK571 (23). In con-
trast, BAY-u9773, which desensitizes the CysLT2 receptor
and blocks the CysLT1 receptor (24), elicited a small cal-
cium flux and partly blocked calcium flux in response to
LTC
 
4
 
 but not LTD
 
4
 
. Priming with IL-4 markedly en-
hanced the sensitivity of hMCs to exogenous cys-LTs, with
the EC50 for MK571-sensitive calcium flux in response to
LTC
 
4
 
 being decreased by 3.8 logs and that to LTD
 
4
 
 by 1.3
logs. Furthermore, the IL-4–induced sensitivity of hMCs
to LTC
 
4
 
 was accompanied by a parallel enhancement of
their sensitivity for calcium flux to a nucleotide agonist,
uridine diphosphate (UDP), which was also blocked by
MK571. LTC
 
4
 
 and UDP cross-desensitized IL-4–primed
hMCs to their respective calcium fluxes, whereas UDP did
not desensitize hMCs to LTD
 
4
 
. These IL-4–induced
changes in the sensitivity of hMCs to LTC
 
4
 
 and UDP oc-
curred without obvious changes in the levels of CysLT1
receptor protein or transcript, and without inducing the
expression of the CysLT2 receptor (23). The augmented
receptor-mediated response of hMCs primed with IL-4 to
cys-LTs and UDP, termed CysLTR
 
IL-4
 
, could reflect the
induction of a previously unrecognized receptor gene, or
the posttranslational modification of the conventional
CysLT1 receptor.
The observations that IL-4 priming of hMCs increased
both the expression of LTC
 
4
 
S (22) and the receptor-medi-
ated responses of these cells to cys-LTs prompted us to seek
a feedback effect. Because IL-4 also primes hMCs for aug-
mented Fc
 
 
 
RI-mediated cytokine generation (2, 25), we
speculated that CysLTR
 
IL-4
 
 might mediate ligand-induced
cytokine gene expression. In this study, we demonstrate
that the ligands for CysLTR
 
IL-4
 
 (cys-LTs and UDP) induce
de novo expression and secretion of the proinflammatory
cytokines IL-5, macrophage inflammatory protein (MIP)-
1
 
 
 
, and TNF-
 
 
 
 by hMCs. Cytokine generation induced
by cys-LTs and UDP is sensitive to inhibition by MK571,
occurs without histamine release or PGD
 
2
 
 generation, and
involves de novo nuclear factor of activated T cells (NF-
AT)-dependent transcription. The findings link hMCs and
cys-LTs to a novel receptor-mediated pathway for cytokine
gene expression that is modulated by IL-4, intersects
ligands of the cys-LT and pyrimidinergic classes, and func-
tions independently of exocytosis. This pathway could be
involved in MC-mediated amplification of innate as well as
adaptive immune responses.
 
Materials and Methods
 
Culture, Priming, and Stimulation of hMCs.
 
hMCs were de-
rived from human umbilical cord blood as described (21). Briefly,
cord blood was obtained from human placentas after routine cae-
sarian sections in accordance with established institutional guide-
lines. Whole heparin-treated cord blood was sedimented with
4.5% dextran solution to remove erythrocytes. The buffy coats
were layered onto 1.77 g/L Ficoll-Hypaque (Amersham Pharma-
cia Biotech), and mononuclear cell interfaces were obtained after
centrifugation. Residual erythrocytes were removed by hypo-
tonic lysis. The remaining mononuclear cells were suspended in
RPMI 1640 (GIBCO BRL) containing 10% fetal bovine serum,
2 mM L-glutamine, 0.1 mM nonessential amino acids, 100 U/ml
penicillin, 100 mg/ml streptomycin, 2 
 
 
 
g/ml gentamycin (all
from Sigma-Aldrich), and 0.2 
 
 
 
M 2-me (GIBCO BRL). Cells
were seeded at a concentration of 10
 
6
 
 cells/ml and were cultured
in the presence of 100 ng/ml SCF (Amgen), 50 ng/ml IL-6
(R&D Systems), and 10 ng/ml IL-10 (Endogen). The nonadher-
ent cells were transferred every week for up to 9 wk into culture
medium containing fresh cytokines. Cytospin preparations were
examined weekly from samples of 2 
 
 
 
 10
 
4
 
 cells with a cytocen-
trifuge (Shandon) and were stained with toluidine blue to assess
metachromasia. hMCs were harvested for study when 
 
 
 
95%
stained positively with toluidine blue (typically 6–9 wk).
For stimulation, cultures of hMCs were washed extensively
and resuspended at a concentration of 10
 
6
 
/ml fresh medium con-
taining SCF (100 ng/ml) alone or with recombinant IL-4 (10
ng/ml). After 4 d, human myeloma IgE (2 
 
 
 
g/ml) was added.
The next day, the cells were again washed and resuspended at a
concentration of 0.5 
 
 
 
 10
 
6
 
/ml in fresh medium containing SCF
(100 ng/ml). They were then distributed to the wells of 96-well
flat-bottom microtiter assay plates in samples of 10
 
5
 
 cells for stim-
ulation in triplicate at 37
 
 
 
C with one of the following agonists:
LTC
 
4
 
 or LTD
 
4
 
 (10
 
 
 
7
 
 M; both from Cayman Chemical), UDP
(10
 
 
 
6
 
 M; Sigma-Aldrich), or a rabbit anti–human IgE Ab (1 
 
 
 
g/
ml; Calbiochem). The final concentrations of the agonists were
chosen on the basis of the doses necessary to elicit maximal gen-
eration of each cytokine from IL-4–primed hMCs and were the 
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same concentrations that elicited maximal calcium fluxes in our
previous study (23). Medium alone was added to some wells as a
negative control. In the initial experiments, serine borate (50
 
 
 
M) was included in the samples treated with LTC
 
4
 
 to inhibit its
conversion to LTD
 
4
 
. This step was subsequently omitted because
the cytokine quantities detected in the LTC
 
4
 
-stimulated samples
were the same with or without serine borate and because HPLC
of LTC
 
4
 
-stimulated hMC supernatants contained no detectable
LTD
 
4
 
, indicating that no conversion had occurred. Some cell
samples were preincubated for 1 min before ligand addition with
the following inhibitors: MK571 (1 or 10 
 
 
 
M), a competitive
antagonist of the CysLT1 receptor (14); MK886 (1 
 
 
 
M), an in-
hibitor of FLAP (26) and LTC
 
4
 
S (27) (both from Cayman); the
selective MEK inhibitor UO126 (5 
 
 
 
g/ml, Promega) (28); and
the calcineurin inhibitor FK506 (29) (10 ng/ml; Fujisawa Health
Care). For histamine release and eicosanoid production, the reac-
tions were terminated at 30 min. Both supernatants and pellets
were collected for measurement of histamine to allow calculation
of percent release (2). For cytokine generation, the reactions
were terminated at 6 h, the time at which the highest levels of
each cytokine were detectable. All samples were frozen at 
 
 
 
20
 
 
 
C
until analysis. The quantities of cytokines were determined for
each sample with commercial ELISA kits (Endogen) with the
manufacturer’s protocol. PGD
 
2
 
, histamine (Cayman), and cys-
LTs (Amersham Pharmacia Biotech) were each measured by
ELISA. The minimal quantities of cytokines, released histamine,
and PGD
 
2
 
 detected in the sham-stimulated samples were sub-
tracted from the other samples in each experiment, and the data
were expressed as the net production in response to each agonist
based on the mean of the replicate experiments indicated in the
text.
 
Steady-State RNA Analysis.
 
Preliminary experiments re-
vealed that each agonist elicited maximal steady-state levels of
each cytokine at 2 h, and this was therefore chosen as the harvest
point in each subsequent experiment. Total RNA was extracted
from 10
 
7
 
 cells with TRI-reagent according to the manufacturer’s
protocol (Molecular Research Center). After extraction with
chloroform followed by overnight precipitation in isopropanol,
total RNA was washed with 70% ethanol, and purity was as-
sessed by spectrophotometry (Beckman DU 640; Beckman
Coulter). Then, 10–15 
 
 
 
g of total RNA was loaded into a 1.2%
agarose gel with 1
 
  
 
MOPS (3-[N-morpholino] propan-sulfonic
acid) buffer containing 20% formaldehyde. After electrophoresis,
RNA was transferred to nylon membranes (Micron Separations)
by capillary action overnight. RNA was fixed to the membrane
by baking at 80
 
 
 
C for 1 h. The blot was prehybridized in 5
 
 
 
standard sodium phosphate with EDTA (SSPE; GIBCO BRL)
containing 2
 
 
 
 Denhardt’s solution, 0.25% SDS, 50% forma-
mide, and 100 
 
 
 
g/ml denatured salmon sperm DNA (GIBCO
BRL) overnight at 43
 
 
 
C. The blot was then probed with previ-
ously described probes for human IL-5 and TNF-
 
 
 
 (2). A MIP-
1
 
 
 
 probe was developed by PCR from hMC RNA that had
been reverse-transcribed with a commercial kit (CLONTECH
Laboratories, Inc.). Briefly, 10 pmol each of a sense strand
(5
 
 
 
-CACACGAATCAAATGTGTTATCC-3
 
 
 
) and an anti-
sense strand (5
 
 
 
-AAGCTTCTGAGTTCTGCAGCCT-3
 
 
 
) primer
were added to a 50-
 
 
 
l reaction mixture containing 10 
 
 
 
l of di-
luted reverse-transcribed RNA, 1
 
 
 
 PCR buffer containing 1.5
mM MgCl
 
2
 
, 200 
 
 
 
M dCTP, dTTP, dGTP, and dATP, (Per-
kinElmer), and 2.5 U of Taq polymerase (PerkinElmer). The
appropriately sized band was visualized on an ethidium bromide-
stained 1.5% agarose gel after 30 cycles of amplification in an au-
tomated thermal cycler (PerkinElmer) with the following param-
 
eters: 94
 
 
 
C for 1 min, 60
 
 
 
C for 1 min, and 72
 
 
 
C for 1 min. The
identity of the probe was subsequently confirmed by automated
sequencing (Dana Farber Cancer Institute Molecular Biology
Core Facility). The blots were also probed with a human 18S
RNA probe (CLONTECH Laboratories, Inc.). Each probe was
randomly labeled with [
 
32
 
P]dCTP with RediPrime II (Amer-
sham Pharmacia Biotech). Blots were washed at high stringency
with 0.2
 
 
 
 SSPE at 55
 
 
 
C, and hybridization signals were de-
tected by autoradiography with Kodak XAR film (Eastman
Kodak Co.). Because of a low to negligible signal on RNA blots,
reverse transcription (RT)-PCR was used to detect steady-state
TNF-
 
  mRNA, with 35 cycles of amplification under the con-
ditions described above with specific commercial primers
(CLONTECH Laboratories, Inc.).
SDS-PAGE Immunoblot Analysis. Samples of 2   105 hMCs
were stimulated for various intervals with LTD4, LTC4 (10 7 M
each), or UDP (10 6 M) in the presence or absence of UO126 (5
 g/ml). The reactions were stopped on ice at the appropriate
times and the cells were lysed in a buffer containing 1% SDS, 1%
Triton X-100, 1 mM EDTA, 1 mM EGTA, 0.2 mM PMSF, 5
 g/ml leupeptin, and 1  g/ml pepstatin in 10 mM Tris (pH
8.0). The samples were loaded with an equal volume of Tris-gly-
cine-SDS loading buffer (Novex) onto precast 12% Tris-glycine-
SDS gels, and the proteins were separated by electrophoresis at
30 mA and 150 mV. After overnight transfer to polyvinylidene
difluoride (PVDF) membranes (Bio-Rad Laboratories), the blots
were blocked for 1 h in 1  Tris-buffered saline with 0.5%
Tween-20 (Bio-Rad Laboratories; TTBS) containing 3% nonfat
dry milk and 0.25% normal goat serum, and incubated in the
same buffer containing 1:2,000 dilutions of anti-Active™ extra-
cellular regulated kinase (ERK), c-Jun NH2-terminal kinase
(JNK), and p38 mitogen-activated protein (MAP) kinase anti-
bodies (Promega) for 2 h at room temperature. After extensive
washing in TTBS, the blots were incubated again for 1 h in
blocking buffer with a 1:5,000 dilution of a goat anti–rabbit
horseradish peroxidase-conjugated secondary Ab (Bio-Rad Lab-
oratories). The blots were washed again in TTBS and bands were
detected using enhanced chemiluminescence (ECL). The same
blots were stripped and probed again with rabbit polyclonal anti-
bodies that detect total ERK, p38, and JNK at dilutions of
1:2,000 (Cell Signaling Technologies). Maximal phosphorylation
of ERK was observed at 5 min, and this was chosen as the har-
vest time for subsequent experiments.
Statistics. The net data from triplicate samples were calculated
for each experiment and were expressed as means   SEM. Dif-
ferences between groups were compared with the paired Stu-
dent’s t test, and P   0.05 was considered significant.
Results
Cytokine (IL-5, MIP1- , TNF- ) Generation by hMCs
With and Without Priming by IL-4. hMCs that were
primed for 5 d with IL-4 in the presence of SCF or were
maintained in SCF alone were stimulated with a range of
concentrations of cys-LTs (10 7–10 9 M) or UDP (10 6–
10 9 M) for 6 h. Unprimed hMCs did not produce either
IL-5 or TNF-  when treated with LTD4 or LTC4 at doses
of 10 9–10 7 M, or in response to UDP at doses up to
10 6 M (n    3 for each cytokine). In contrast, hMCs
primed with IL-4 generated IL-5 in response to the highest
tested doses of LTC4, LTD4, and UDP (29   7, 38   9,
and 11   2 pg/106 hMCs, respectively; Fig. 1 A, n   5 for586 Cysteinyl Leukotrienes Induce Mast Cell Cytokine Production
each agonist). The same three ligands also induced the gen-
eration of TNF-  (16   10, 22   9, and 31   10 pg/106
hMCs, n   3 for each agonist) by the IL-4–primed hMCs.
In the unprimed hMCs, LTC4 and LTD4 each induced the
generation of MIP-1  (622   286 pg and 508   350 pg/
106 hMCs, respectively, n   5) at the highest doses tested,
while UDP induced MIP-1  production at doses of 10 7 M
(670 pg/106 hMCs, not shown), and 10 6 M (2,836   990
pg/106 hMCs; Fig. 1 A, n   5). MIP-1  production by
IL-4–primed hMCs was induced by all three agonists at
doses as low as 10 9 M and was substantially enhanced in
response to the highest agonist concentrations used (2,428  
670, 3,018   848, and 4,572   1,660 pg/106 hMCs in re-
sponse to LTC4, LTD4, and UDP, respectively, P   0.02,
0.11, and 0.005 compared with unprimed conditions, n  
4 for each agonist; Fig. 1 A).
2 h after stimulation, LTC4, LTD4, and UDP each in-
duced increases in the steady-state levels of mRNA encod-
ing TNF- , IL-5, and MIP-1  compared with the levels
detected in the sham controls. The IL-5 and MIP-1  hy-
bridization signals induced by LTC4 and LTD4 were gen-
erally equivalent to one another in intensity (n   4, as
shown for one experiment; Fig. 1 B), and usually exceeded
the UDP-induced signals. In contrast, UDP-induced
TNF-  mRNA signals were consistently stronger than
those elicited by cys-LTs as detected by RT-PCR (n   3,
as shown for one experiment; Fig. 3 B). The signals in-
duced by each agonist were lower than those generated in
response to IgE receptor cross-linkage (n   3, as shown for
one donor; Fig. 1 B).
Effect of MK571 on Cytokine Generation by Primed
hMCs. To define the class of the receptors mediating the
induction of cytokine expression in response to cys-LTs
and UDP, the IL-4–primed hMCs were treated for 1 min
with MK571 before ligand was added. 10-fold molar ex-
cesses of MK571 (1  M) blocked MIP-1  generation in
response to 10 7 M LTC4 and LTD4 by  90% (Fig. 2; P  
0.07 and 0.03, respectively, n   6). The same concentra-
tion of MK571 also partly and significantly blocked UDP-
induced MIP-1  production (31% inhibition, P   0.05;
Fig. 2, n   6), and blocked UDP-induced MIP-1  genera-
tion to a greater extent at 10  M (75% inhibition; Fig. 2,
Figure 1. (A) Effect of IL-4
priming on cys-LT– and UDP-
mediated cytokine generation by
hMCs. P values reflect increases
in ligand-induced product due to
IL-4 priming (black bars) relative
to the unprimed replicates
(white bars). Results are based
on n   3 for TNF-  and n   5
for both MIP-1  and IL-5. * in-
dicates P   0.05 and ** indicates
P   0.01. (B) Steady-state levels
of mRNA encoding IL-5 and
MIP-1  (by RNA blot) and
TNF-  (by RT-PCR). The dis-
played signals are from a single experiment representative of four (for
IL-5 and MIP-1 ) and three (for TNF- ) performed.
Figure 2. Effect of MK571 pretreatment of IL-4–primed hMCs on cy-
tokine generation in response to cys-LTs and UDP. Data reflect the
means   SEM for 6–12 experiments, except for the higher-dose MK571-
treated samples, which reflect n   3 for TNF-  and MIP-1 , and n   1
for IL-5. * indicates P   0.05, while ** indicates P   0.01.587 Mellor et al.
n   2). MK571 at 1  M profoundly blocked production of
both IL-5 and TNF-  in response to LTC4 (86   7% and
83   17% inhibition; n   6), and to LTD4 (94   3% and
96   4% inhibition; n   6). This dose of MK571 partially
but significantly blocked UDP-induced IL-5 generation
(37   17% inhibition, n   12, P   0.04). However, a
higher (10  M) dose of MK571 was required to diminish
TNF-  generation in response to 1  M UDP (72   28%
inhibition, P   0.03, n   3; Fig. 2).
Effect of Cys-LT Receptor Antagonism and Cys-LT Synthesis
Inhibition on Fc RI-mediated Cytokine Generation. IL-4–
primed hMCs generated substantial quantities of IL-5
(84   18 pg/106 hMCs, n   13), TNF-  (604   173 pg/106
hMCs, n   8; Fig. 3) and MIP-1  (28,476   8,600 pg/106
hMCs, n   4, not shown) after passive sensitization and
challenge. Pretreatment with MK571 (1  M) to block ac-
cess to the CysLT1 and CysLTRIL-4 receptors partially and
significantly attenuated the generation of IL-5 (29   5%
inhibition, P   0.008, n   13; Fig. 3), and of TNF-  (33  
6% inhibition, P   0.03, n   8; Fig. 3) to a comparable
extent. In five experiments, hMCs pretreated with the
FLAP/LTC4S inhibitor MK886 (1  M), were inhibited by
31   5% and 26   6%, respectively, for IL-5 and TNF- 
generation (P   0.05 and 0.005, respectively; Fig. 3); this
finding was similar to that for MK571-treated hMCs. By
comparison, interference by MK571 and MK886 with the
substantial IgE-dependent generation of MIP-1  did not
approach significance (data not shown). Neither agent af-
fected IgE-dependent histamine release (data not shown).
As anticipated, MK886 nearly completely blocked cys-LT
generation by IL-4–primed hMCs (from 9   3 to 0.024  
0.004 pg/106 hMCs), whereas MK571 had no effect (n  
2, data not shown).
Effect of Stimulation of hMCs with Cys-LTs or UDP on
Exocytosis and PGD2 Generation. IL-4–primed hMCs
stimulated with maximal concentrations of cys-LTs (10 7
M) or UDP (10 6 M) were studied 30 min after activation
for their metachromatic staining with toluidine blue, their
release of histamine, their generation of PGD2, and, in the
case of UDP, their production of cys-LTs. Replicate hMCs
were passively sensitized and stimulated with an anti-IgE
Ab or with a sham control. Toluidine blue staining of
hMCs at both 30 min (Fig. 4, top) and 6 h (not shown) af-
ter stimulation revealed loss of granules in the anti–IgE–
stimulated groups, but not in the groups stimulated with
UDP or cys-LTs (n   3, representative experiment shown;
Fig. 4, top panels). Anti-IgE caused histamine release (46  
3%,  n    3; Fig. 4), cys-LT generation (9   3 ng/106
hMCs, mean   1/2 range, n   2, data not shown), and
PGD2 production (12   6 ng/106 hMCs, mean   1/2
range, n   2; Fig. 4) by IL-4–primed hMCs. In contrast,
LTC4, LTD4, and UDP did not induce exocytosis of hista-
mine (n   3; Fig. 4), PGD2 production (n   2; Fig. 4), or,
in the case of UDP, cys-LT production (n   2, data not
shown). Sham-treated hMCs retained their metachromatic
granules, and did not release histamine, produce PGD2, or
generate cys-LTs (n   3, not shown).
Involvement of NF-AT and ERK Signaling Pathways in
Cys-LT- and UDP-Mediated Cytokine Generation. Stimu-
lation of hMCs for 5 min with 10 7 M concentrations of
LTC4 and LTD4 or with 10 6 M concentrations of UDP
resulted in phosphorylation of ERK (Fig. 5 A). Phosphory-
lation of p38 MAP kinase was constitutive and not in-
creased during the 5 min stimulation by any ligand, while
phosphorylation of JNK was not detected (not shown). For
each agonist, the phosphorylation of ERK was reduced to
levels below baseline by a 5-min pretreatment with the se-
lective mitogen-activated protein ERK kinase inhibitor
U0126 (5  g/ml; Fig. 5 A). Pretreatment of IL-4–primed
hMCs with either UO126 or the calcineurin inhibitor,
FK506 (10 ng/ml), almost completely blocked their gener-
ation of both IL-5 and MIP-1  in response to cys-LTs and
UDP (Fig. 5 B). TNF-  production was also blocked by
both inhibitors, although not completely in the cases of
LTD4 (77   17 and 69   20% inhibition in response to
UO126 and FK506, respectively) and UDP (84   10 and
56   26% inhibition, respectively; Fig. 5 B).
Discussion
We describe a novel function for cys-LTs through their
receptors, namely, the induction of proinflammatory cy-
tokine gene expression and protein secretion by hMCs
that does not involve exocytosis. As with calcium flux, the
induction of cytokines is blocked by a selective, competi-
tive CysLT1 receptor antagonist, MK571. The maximal
induction of this function requires priming of the hMCs
by IL-4, which on the basis of our prior studies does not
induce significant changes in the expression of the known
cys-LT receptors (23); thus we use Cys-LTRIL-4 to desig-
Figure 3. Effect of receptor blocker (MK571) and FLAP inhibitor
(MK886) on IL-5 and TNF-  generation by IL-4–primed and sensitized
hMCs stimulated with anti-IgE without (white bars) and with (black bars)
inhibitors. Results for MK571 (left) reflect mean   SEM for 13 (IL-5)
and 8 (TNF- ) experiments. Results for MK886 (right) reflect five of
those experiments. * indicates P   0.05, while ** indicates P   0.01.588 Cysteinyl Leukotrienes Induce Mast Cell Cytokine Production
nate the recognition/effector step. A key implication of
these findings is that cys-LTs generated by eosinophils,
macrophages, and hMCs could induce hMC-derived
proinflammatory cytokines such as TNF-  without evi-
dence of degranulation. This mechanism could operate in
the setting of allergic and asthmatic inflammation, where
IL-4 is prominently expressed by T cells. In innate immu-
nity, natural killer T cells could provide IL-4 (30), and the
cys-LTs could be derived by bacterial products acting on
cells directly through  -glucan receptors (31, 32) or indi-
rectly through complement activation products on their
cellular receptors (33). Additionally, UDP provided by mi-
crobes, injured cells, or neurogenic signals (34) could ini-
tiate a similar activation cascade through receptors shared
with cys-LTs on hMCs.
The previous recognition that cys-LT receptors are ex-
pressed by hematopoietic effector cells (18) implies that
cys-LTs have functions distinct from their known, rapid-
onset bronchoactive and vasoactive effects. Our recent ob-
servation that hMCs also express the CysLT1 receptor and
the CysLTRIL-4 led us to hypothesize that cys-LTs might
act through hMCs to initiate cytokine production, ac-
counting for a more sustained, proinflammatory effect. We
therefore stimulated both IL-4–primed and unprimed
hMCs with LTC4, LTD4, and UDP at the dosing ranges
that had elicited maximal calcium responses previously
(23). The sustained calcium fluxes elicited by these ago-
nists in hMCs are typical of those that couple to cytokine
production in T cells (35). MIP-1  was included in our
analysis, because it is a major lymphocyte chemoattractant
that is generated exclusively by MCs in a mouse model of
contact sensitization (36) and is generated abundantly by
the leukemic MC line, HMC-1, activated through the
transfected fMLP receptor (37). IL-5, the eosinophilopoi-
etic cytokine, was included because its IgE-dependent ex-
pression by cord blood–derived hMCs requires priming
with IL-4 (2). TNF-  was measured because of its impor-
tance in MC-dependent host resistance to bacteria (38)
and its role in human diseases such as rheumatoid arthritis
(39). Of these cytokines, only MIP-1  was detected in su-
pernatants from the stimulated, unprimed hMCs, and only
at the highest cys-LT concentrations tested. As was the
case for calcium flux in our previous studies, IL-4 priming
sharply lowered the doses of cys-LTs needed to elicit dose-
dependent MIP-1  generation from 10 7 to 10 9 M; IL-4
priming was required for the detection of IL-5 and TNF- 
Figure 4. Comparison of histamine release and PGD2 generation from IL-4–primed hMCs activated by anti-IgE, cys-LTs, or UDP. Toluidine blue
staining for granules of IL-4–primed, passively sensitized hMCs stimulated with the indicated agonists for 30 min (top), percent release of histamine (middle),
and PGD2 generation in response to the same stimuli (bottom). The depicted toluidine blue stains are from a single experiment representative of three
performed. Histamine release is the mean   SEM for three experiments, while PGD2 generation is the mean   1/2 range for two experiments.589 Mellor et al.
production, which occurred only at the highest agonist
concentrations tested (Fig. 1 A). The fact that the ligand-
initiated cytokine generation depended on de novo gene
induction was supported by two lines of evidence; first,
each agonist induced steady-state IL-5, TNF- , and MIP- 
mRNA expression 2 h after stimulation (Fig. 1 B). Sec-
ond, cytokine generation in response to each agonist was
blocked by the calcineurin-dependent transcription inhibi-
tor FK506 (Fig. 5 B). MK571, the competitive CysLT1
receptor antagonist, blocked the cys-LT–mediated pro-
duction of each cytokine virtually completely (Fig. 2).
Thus, IL-4 priming strongly enhances cys-LT–induced cy-
tokine production, with LTC4 and LTD4 being equipotent
when signaling through the CysLTRIL-4 pathway, as was
observed for calcium flux (23).
The fact that IL-4 priming of hMCs profoundly induces
the expression of LTC4S and IgE-dependent cys-LT gener-
ation (22) suggested the possibility that endogenously gen-
erated cys-LTs could modulate Fc RI-dependent hMC
activation responses through the CysLTRIL-4 pathway.
Pretreatment with MK571 to block access to the CysL-
TRIL-4 and CysLT1 receptors, or with MK886 to inhibit
the production of endogenous cys-LTs did not alter hista-
mine release in response to Fc RI cross-linkage. As ex-
pected, only MK886 blocked cys-LT generation. How-
ever, both MK571 and MK886 attenuated IL-5 production
and TNF-  in response to IgE receptor cross-linkage by
 30%. (Fig. 3). IgE-dependent MIP-1  generation, which
is 40–300-fold greater than that of IL-5 or TNF- , was un-
affected by either inhibitor (data not shown). Thus, endog-
enously produced cys-LTs act through the CysLTRIL-4
pathway to amplify cytokine generation in response
to Fc RI cross-linkage. Furthermore, this amplification
mechanism is especially important for IL-5 and TNF- ,
the two cytokines most dependent on IL-4 priming for
their expression (Fig. 1). The fact that hMCs activated by
IgE receptor cross-linkage released quantities of cys-LTs (9
ng, or 14 pmol/106 hMCs) well below the nanomolar
ranges used for stimulation suggests that endogenously gen-
erated cys-LTs work as ligands in a “synapse” with their re-
ceptors on hMCs. In this context, it is noteworthy that
LTC4 is exported by a specific carrier-dependent mecha-
nism (10), and that the CysLTRIL-4 pathway is marked by
the preferential augmentation of LTC4 responses over those
to LTD4 (23). The participation of endogenous cys-LTs in
the regulation of TNF-  generation was demonstrated in a
mouse model of SCF-induced bronchial inflammation and
hyperreactivity, where MK886 pretreatment attenuated
subsequent pulmonary expression of TNF-  (40).
We used a higher concentration of UDP (10 6 M) than
cys-LTs (10 7 M) because this concentration had been re-
quired to achieve a maximal calcium flux and because this
concentration was necessary to consistently recognize the
IL-4–priming effect in a setting where unprimed hMCs
produced nanogram quantities of MIP-1  in response to
UDP (Fig. 1 A). Although treatment with 1  M MK571
did not completely block UDP-induced production of any
of the three cytokines by IL-4–primed hMCs, the percent
inhibition for MIP-1  was significant and was further en-
hanced when MK571 was used at a 10-fold molar excess
(Fig. 2). The higher concentration of MK571 attenuated
the UDP-mediated production of MIP-1 , TNF- , and
IL-5, although in the latter case the experiment was not re-
peated sufficiently to attain statistical significance. The ap-
parent limitations of MK571 as a UDP antagonist, com-
pared with its full efficacy in blocking cys-LT responses,
could reflect either the differences in the agonist concentra-
tions used or overlapping but nonidentical respective bind-
ing sites for cys-LTs and UDP on the CysLT1 and CysL-
TRIL-4 receptors. The IL-4– and MK571-insensitive
components of UDP-mediated MIP-1  generation, and
Figure 5. Involvement of the ERK and calcineurin/NF-AT pathways
in cys-LT– and UDP-induced cytokine generation by IL-4–primed
hMCs. (A) Anti-phospho-ERK, anti-total ERK, and anti-phospho-p38
immunoblots performed on lysates of hMCs stimulated for 5 min with
LTC4, LTD4, or UDP in the presence ( ) or absence ( ) of the MEK
inhibitor, UO126. Replicate hMCs treated with a sham control (SCF
alone) are included. Results are from a single experiment representative of
four performed. (B) Generation of IL-5, TNF- , and MIP-1  by IL-4–
primed hMCs in the presence or absence of UO126 or FK506. Results
are the mean   SEM of 3–4 experiments. * indicates P   0.05.590 Cysteinyl Leukotrienes Induce Mast Cell Cytokine Production
the differences between the cys-LT– and UDP-stimulated
hMCs in relative levels of elicited steady-state MIP-1 
mRNA and protein secretion, could reflect activation of
uridine binding P2Y receptors. Neither the UTP-binding
P2Y4 receptor, which is expressed by hMCs, nor the
UDP-specific P2Y6 receptor respond to cys-LTs, nor are
they blocked by MK571 when cloned and expressed in
transfected cell lines (23).
In comparison to the extensive literature on Fc RI-
mediated signal transduction, little is known concerning the
pathways used by G protein–coupled receptors for cyto-
kine generation in MCs. MIP-1  production by the
HMC-1 cell line in response to stimulation through the
transfected fMLP receptor involves convergent signaling
through calcineurin-dependent NF-AT transcription fac-
tors and ERK (37). Both cys-LTs and UDP caused phos-
phorylation of ERK that was inhibited by UO126 pretreat-
ment (Fig. 5 A), with the cys-LTs eliciting especially strong
phosphorylation. Both FK506 and UO126 blocked the
production of IL-5 and MIP-1  in response to each agonist
virtually completely, and substantially interfered with
TNF-  generation (Fig. 5 B). Residual TNF-  production
could reflect additional signaling pathways and transcrip-
tion factors, such as nuclear factor  B, which is involved in
the transcriptional control of IgE-dependent TNF-  gen-
eration in the transformed rat MC line, RBL-2H3 (41).
IL-4 priming of hMCs in vitro amplifies their subsequent
exocytosis of histamine and PGD2 generation in response
to IgE receptor cross-linkage, in parallel with up-regulation
of Fc RI expression (42). As anticipated, primed, passively
sensitized hMCs released histamine and generated PGD2 in
response to cross-linkage of Fc RI. However, neither his-
tamine exocytosis nor PGD2 production occurred in re-
sponse to maximally effective doses of cys-LTs or UDP
(Fig. 4). The lack of histamine release was associated with
retention of toluidine blue–positive granules, which con-
trasted sharply with the marked degranulation observed in
the hMCs stimulated by cross-linkage of Fc RI (Fig. 4).
Mouse MCs stimulated with bacterial LPS through toll-like
receptor 4 (TLR4) also generate several proinflammatory
cytokines, including TNF- , through new transcription
and translation, with no exocytosis (43). UDP and the
P2Y6 receptor were recently implicated in an autocrine
feedback mechanism amplifying IL-8 generation by a LPS-
stimulated human monocytic cell line (44). The diversity of
calcium-dependent signaling cascades in MCs may include
overlapping pathways elicited by the cys-LT receptors,
P2Y receptors, and TLR4 to induce cytokine/chemokine
production without concomitant exocytosis.
Our study demonstrates cytokine gene induction by
hMCs through CysLT receptor pathway(s) and an auto-
crine/paracrine amplification mechanism via these recep-
tors for IgE-dependent cytokine generation. In either case,
hMCs stimulated through cys-LT receptors could promote
neutrophil recruitment (through TNF- ), lymphocyte
chemotaxis (through MIP-1 ), and eosinophilia (through
IL-5). These findings may help to explain the observation
that allergen-induced late phase pulmonary responses in
vivo are attenuated by pretreatment with CysLT1 receptor
antagonists (45) and may relate to the observation that
bronchial inflammation and eosinophilia are markedly at-
tenuated in biopsy specimens taken from patients with
asthma who are being treated with CysLT1 receptor antag-
onists (46). Furthermore, the steroid-sparing action of an
inhaled soluble IL-4 receptor (47) could in part reflect inhi-
bition of IL-4 priming for IgE receptor, LTC4S, and CysL-
TRIL-4 expression by hMCs.
This work was supported by National Institutes of Health grants
AI-31599 and HL-36110, The Charles A. Dana Foundation, and a
grant from the Hyde and Watson Foundation.
Submitted: 9 January 2002
Accepted: 29 January 2002
References
1. Boyce, J.A., and K.F. Austen. 2001. Biology of the mast cell.
In Samter’s Immunologic Diseases. K.F. Austen, M.M.
Frank, J.P. Atkinson, and H. Cantor, editors. Lippincott,
Williams and Wilkins, Inc., Philadelphia, PA. 253–274.
2. Ochi, H., N.H. De Jesus, F. Hsieh, K.F. Austen, and J.A.
Boyce. 2000. Interleukins 4 and 5 prime human mast cells for
different profiles of IgE-dependent cytokine production. Proc.
Natl. Acad. Sci. USA. 97:10509–10513.
3. Plaut, M., J.H. Pierce, C.J. Watson, J. Hanley-Hyde, R.P.
Nordan, and W.E. Paul. 1989. Mast cell lines produce lym-
phokines in response to cross-linkage of Fc epsilon RI or to
calcium ionophores. Nature. 339:64–67.
4. Clark, J.D., L.L. Lin, R.W. Kriz, C.S. Ramesha, L.A. Sultz-
man, A.Y. Lin, N. Milona, and J.L. Knopf. 1991. A novel
arachidonic acid-selective cytosolic PLA2 contains a Ca2 -
dependent translocation domain with homology to PKC and
GAP. Cell. 65:1043–1051.
5. Dixon, R.A., R.E. Diehl, E. Opas, E. Rands, P.J. Vickers,
J.F. Evans, J.W. Gillard, and D.K. Miller. 1990. Require-
ment of a 5-lipoxygenase-activating protein for leukotriene
biosynthesis. Nature. 343:282–284.
6. Reid, G.K., S. Kargman, P.J. Vickers, J.A. Mancini, C. Lev-
eille, D. Ethier, D.K. Miller, J.W. Gillard, R.A. Dixon, and
J.F. Evans. 1990. Correlation between expression of 5-lipoxy-
genase-activating protein, 5-lipoxygenase, and cellular leu-
kotriene synthesis. J. Biol. Chem. 265:19818–19823.
7. Nicholson, D.W., A. Ali, J.P. Vaillancourt, J.R. Calaycay,
R.A. Mumford, R.J. Zamboni, and A.W. Ford-Hutchinson.
1993. Purification to homogeneity and the N-terminal se-
quence of human leukotriene C4 synthase: A homodimeric
glutathione S-transferase composed of 18-kDa subunits. Proc.
Natl. Acad. Sci. USA. 90:2015–2019.
8. Lam, B.K., J.F. Penrose, G.J. Freedman, and K.F. Austen.
1994. Expression cloning of a cDNA for human leukotriene
C4 synthase, a novel integral membrane protein conjugating
reduced glutathione to leukotriene A4. Proc. Natl. Acad. Sci.
USA. 91:7663–7669.
9. Welsch, D.J., D.P. Creely, S.D. Hauser, K.J. Mathis, G.G.
Krivi, and P.C. Isakson. 1994. Molecular cloning and expres-
sion of human leukotriene C4 synthase. Proc. Natl. Acad. Sci.
USA. 91:9745–9749.
10. Lam, B.K., W.F. Owen, K.F. Austen, and R.J. Soberman.
1989. The identification of a distinct export step following591 Mellor et al.
the biosynthesis of leukotriene C4 by human eosinophils. J.
Biol. Chem. 264:12885–12891.
11. Anderson, M.E., R.D. Allison, and A. Meister. 1982. Inter-
conversion of leukotrienes catalyzed by purified  -glutamyl
transpeptidase: concomitant formation of leukotriene D4 and
 -glutamyl amino acids. Proc. Natl. Acad. Sci. USA. 79:1088–
1091.
12. Shi, Z.-Z., B. Han, G.M. Habib, M.M. Matzuk, and M.W.
Lieberman. 2001. Disruption of  -glutamyl leukotrienease
results in disruption of leukotriene D4 synthesis in vivo and
attenuation of the acute inflammatory response. Mol. Cell.
Biol. 21:5389–5395.
13. Lee, C.W., R.A. Lewis, E.J. Corey, and K.F. Austen. 1983.
Conversion of leukotriene D4 to leukotriene E4 by a dipepti-
dase released from the specific granules of human polymor-
phonuclear leukocytes. Immunology. 48:27–35.
14. Lynch, K.R., G.P. O’Neill, Q. Liu, D.S. Im, N. Sawyer,
K.M. Metters, N. Coulombe, M. Abramovitz, D.J. Figueroa,
Z. Zeng, et al. 1999. Characterization of the human cysteinyl
leukotriene CysLT1 receptor. Nature. 399:789–793.
15. Heise, C.E., B.F. O’ Dowd, D.J. Figueroa, N. Sawyer, T.
Nguyen, D.S. Im, R. Stocco, J.N. Bellefeuille, M. Abramo-
vitz, R. Cheng, et al. 2000. Characterization of the human
cysteinyl leukotriene 2 receptor. J. Biol. Chem. 275:30531–
30536.
16. Davidson, A.B., T.H. Lee, P.D. Scanlon, J. Solway, E.R.
McFadden, R.H. Ingram, E.J. Corey, K.F. Austen, and J.M.
Drazen. 1987. Bronchoconstrictor effects of leukotriene E4 in
normal and asthmatic subjects. Am. Rev. Respir. Dis. 135:
333–337.
17. Soter, N.A., R.A. Lewis, E.J. Corey, and K.F. Austen. 1983.
Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4,
and LTB4) in human skin. J. Invest. Dermatol. 80:115–119.
18. Figueroa, D.J., R.M. Breyer, S.K. Defoe, S. Kargman, B.L.
Daugherty, K. Waldburger, Q. Liu, M. Clements, Z. Zeng,
G.P. O’Neill, et al. 2001. Expression of the cysteinyl leuko-
triene 1 receptor in normal human lung and peripheral blood
leukocytes. Am. J. Respir. Crit. Care Med. 163:226–233.
19. Bautz, F., C. Denzlinger, L. Kanz, and R. Mohle. 2001.
Chemotaxis and transendothelial migration of CD34( ) he-
matopoietic progenitor cells induced by the inflammatory
mediator leukotriene D4 are mediated by the 7-transmem-
brane receptor CysLT1. Blood. 97:3433–3440.
20. Laitinen, L.A., A. Laitinen, T. Haahtela, V. Vilkka, B.W.
Spur, and T.H. Lee. 1992. Leukotriene E4 and granulocytic
infiltration into asthmatic airways. Lancet. 341:989–990.
21. Ochi, H., W.M. Hirani, Q. Yuan, D. Friend, K.F. Austen,
and J.A. Boyce. 1999. T helper type 2 cytokine-mediated co-
mitogenic responses and CCR3 expression during differenti-
ation of human mast cells in vitro. J. Exp. Med. 190:267–280.
22. Hsieh, F.H., B.K. Lam, J.F. Penrose, K.F. Austen, and J.A.
Boyce. 2001. T helper cell type 2 cytokines coordinately reg-
ulate IgE-dependent cysteinyl leukotriene production by hu-
man cord blood-derived mast cells: Profound induction of
leukotriene C4 synthase expression by interleukin 4. J. Exp.
Med. 193:123–133.
23. Mellor, E.A., K.F. Austen, and J.A. Boyce. 2001. Cysteinyl
leukotriene receptor 1 is also a pyrimidinergic receptor and is
expressed by human mast cells. Proc. Natl. Acad. Sci. USA.
98:7964–7969.
24. Nothacker, H.P., Z. Wang, Y. Zhu, R.K. Reinscheid, S.H.
Lin, and O. Civelli. 2000. Molecular cloning and character-
ization of a second human cysteinyl leukotriene receptor: dis-
covery of a subtype selective agonist. Mol. Pharmacol. 58:
1601–1608.
25. Toru, H., R. Pawankar, C. Ra, J. Yata, and T. Nakahata.
1998. Human mast cells produce IL-13 by high-affinity IgE
receptor cross-linking: enhanced IL-13 production by IL-4-
primed human mast cells. J. Allergy Clin. Immunol. 102:491–
502.
26. Rouzer, C.A., A.W. Ford-Hutchinson, H.E. Morton, and
J.W. Gillard. 1990. MK886, a potent and specific leukotriene
biosynthesis inhibitor blocks and reverses the membrane as-
sociation of 5-lipoxygenase in ionophore-challenged leuko-
cytes. J. Biol. Chem. 265:1436–1442.
27. Lam, B.K., J.F. Penrose, K. Xu, M.H. Baldasaro, and K.F.
Austen. 1997. Site-directed mutagenesis of human leuko-
triene C4 synthase. J. Biol. Chem. 272:13923–13928.
28. Newton, R., L. Cambridge, L.A. Hart, D.A. Stevens, M.A.
Lindsay, and P.J. Barnes. 2000. The MAP kinase inhibitors,
PD098059, UO126 and SB203580, inhibit IL-1 -dependent
PGE2 release via mechanistically distinct processes. Br. J.
Pharmacol. 130:1353–1361.
29. Liu, J., J.D. Farmer, Jr., W.S. Lane, J. Friedman, I. Weiss-
man, and S.L. Schreiber. 1991. Calcineurin is a common tar-
get of cyclophilin-cyclosporin A and FKBP-FK506 com-
plexes. Cell. 66:807–815.
30. Kadowaki, N., S. Antonenko, S. Ho, M.C. Rissoan, V.
Soumelis, S.A. Porcelli, L.L. Lanier, and Y.J. Liu. 2001. Dis-
tinct cytokine profiles of neonatal natural killer T cells after
expansion with subsets of dendritic cells. J. Exp. Med. 193:
1221–1226.
31. Czop, J.K., A.V. Puglisi, D.Z. Miorandi, and K.F. Austen.
1988. Perturbation of  -glucan receptors on human neutro-
phils initiates phagocytosis and leukotriene B4 production. J.
Immunol. 141:3170–3176.
32. Brown, G.D., and S. Gordon. 2001. Immune recognition. A
new receptor for beta-glucans. Nature. 413:36–37.
33. Bischoff, S.C., A.L. de Weck, and C.A. Dahinden. 1990. In-
terleukin 3 and granulocyte/macrophage-colony-stimulating
factor render human basophils responsive to low concentra-
tions of complement component C3a. Proc. Natl. Acad. Sci.
USA. 87:6813–6817.
34. Von Kugelgen, I., and A. Wetter. 2000. Molecular pharma-
cology of P2Y-receptors. Naunyn-Schmiedeberg’s Arch. Phar-
macol. 362:310–323.
35. Timmerman, L.A., N.A. Clipstone, S.N. Ho, J.P. Northrop,
and G.R. Crabtree. 1996. Rapid shuttling of NF-AT in dis-
crimination of Ca2  signals and immunosuppression. Nature.
383:837–840.
36. Tedla, N., H.W. Wang, H.P. McNeil, N. Di Girolamo, T.
Hampartzoumian, D. Wakefield, and A. Lloyd. 1998. Regu-
lation of T lymphocyte trafficking into lymph nodes during
an immune response by the chemokines macrophage inflam-
matory protein (MIP)-1 alpha and MIP-1 beta. J. Immunol.
161:5663–5672.
37. Ali, H., J. Ahamed, C. Hernandez-Munain, J.L. Baron, M.S.
Krangel, and D.D. Patel. 2000. Chemokine production by G
protein-coupled receptor activation in a human mast cell
line: roles of extracellular signal-regulated kinase and NFAT.
J. Immunol. 165:7215–7223.
38. Echtenacher, B., D.N. Mannel, and L. Hultner. 1996. Criti-
cal protective role of mast cells in a model of acute septic
peritonitis. Nature. 381:75–79.
39. Woolley, D.E., and L.C. Tetlow. 2000. Mast cell activation
and its relation to proinflammatory cytokine production in592 Cysteinyl Leukotrienes Induce Mast Cell Cytokine Production
the rheumatoid lesion. Arth. Res. 2:65–74.
40. Oliveira, S.H., C.M. Hogaboam, A. Berlin, and N.W.
Lukacs. 2001. SCF-induced airway hyperreactivity is depen-
dent on leukotriene production. Am. J. Physiol. Lung Cell.
Mol. Physiol. 280:L1242–1249.
41. Pelletier, C., N. Varin-Blank, J. Rivera, B. Iannascoli, F.
Marchand, B. David, A. Weyer, and U. Blank. 1998. Fc RI-
mediated induction of TNF-  gene expression in the RBL-
2H3 mast cell line: regulation by a novel NF- B-like nuclear
binding complex. J. Immunol. 161:4768–4776.
42. Yamaguchi, M., K. Sayama, K. Yano, C.S. Lantz, N.
Noben-Trauth, C. Ra, J.J. Costa, and S.J. Galli. 1999. IgE
enhances Fc epsilon receptor I expression and IgE-dependent
release of histamine and lipid mediators from human umbili-
cal cord blood-derived mast cells: synergistic effect of IL-4
and IgE on human mast cell Fc epsilon receptor I expression
and mediator release. J. Immunol. 162:5455–5465.
43. Supajatura, V., H. Ushio, A. Nakao, K. Okumura, C. Ra,
and H. Ogawa. 2001. Protective roles of mast cells against
enterobacterial infection are mediated by toll-like receptor 4.
J. Immunol. 167:2250–2256.
44. Warny, M., S. Aboudola, S.C. Robson, J. Sevigny, D. Com-
muni, S.P. Soltoff, and C.P. Kelly. 2001. P2Y6 nucleotide
receptor mediates monocyte interleukin-8 production in re-
sponse to UDP or lipopolysaccharide. J. Biol. Chem. 276:
26051–26056.
45. Hamilton, A., I. Faiferman, P. Stober, R.M. Watson, and
P.M O’Byrne. 1998. Pranlukast, a cysteinyl leukotriene re-
ceptor antagonist, attenuates allergen-induced early- and late-
phase bronchoconstriction and airway hyperresponsiveness in
asthmatic subjects. J. Allergy Clin. Immunol. 102:177–183.
46. Nakamura, Y., M. Hoshino, J.J. Sim, K. Ishii, K. Hosaka,
and T. Sakamoto. 1998. Effect of the leukotriene receptor
antagonist pranlukast on cellular infiltration in the bronchial
mucosa of patients with asthma. Thorax. 53:835–841.
47. Borish, L.C., H.S. Nelson, J. Corren, G. Bensch, W.W.
Busse, J.B. Whitmore, and J.M. Agosti. 2001. IL-4R Asthma
Study Group. Efficacy of soluble IL-4 receptor for the treat-
ment of adults with asthma. J. Allergy Clin. Immunol. 107:
963–970.